In vitro study | Scriptaid(6 μm) acted on PANC-1 cells to increase histone acetylation by more than 100-fold. Scriptaid(8 μm) is non-lethal to PANC-1 cells and has a limiting effect on MDA-MB-468 (80% survival). Scriptaid increases pCMVb, p6SBE-luc-and p6MBE-luc-independent transcription. Scriptaid can induce high expression of p6MBE-luc, pCMVb, and pUB6/V5-LacZ driven by viral (SV40 and CMV) or human (Ubiquitin c, UB6) promoters, this does not depend on the specificity of the enhancer (SBE and MBE), the type of promoter (viral and cellular), the product of the reporter gene (luciferase and β-galactosidase), and the integration status of the reporter gene structure. Scriptaid induces a high incidence of human nuclear transfer (SCNT) in oocytes developing to the blastocyst stage, and at all concentrations (50,100,250,500 and 2000 nm, respectively). All allowed their full-term development (3.4,4.2,7.6,6.8, and 4.1 percent, respectively). Scriptaid promoted the full-term development of cloned B6D2F1 embryos in a dose-dependent manner, with a maximum effect at 250 nm. Scriptaid clones all important inbred mouse strains such as C57BL/6, C3H/He, DBA/2, and 129/Sv. Scriptaid treatment of cloned embryos enhances the level of newly synthesized mRNA. Treatment of ICSI-fertilized embryos with 250 nM Scriptaid for up to 48 H did not inhibit development. Scriptaid inhibits the proliferation of T. gondii tachyzoite with an IC50 of 39 nM. Scriptaid(0.225 μm) completely protected HS68 monolayers from T. gondii tachyzoite invasion. Scriptaid inhibited the growth of ER-negative cell lines MDA-MB-231, MDA-MB-435, and Hs578t with an IC50 of 0.5-1.0 μg/mL after 48 h of treatment. 1 μg/ml Scriptaid treatment for 48 hours, induced the accumulation of acetylated H3 and H4 histone tail proteins, promoted ER mRNA transcription, and increased by 20000 times. Scriptaid inhibits the proliferation and viability of Ishikawa endometrial cancer cell line, and SK-OV-3 ovarian cancer cell lines with IC50 of 9 μm and 55 μm, respectively, while showing little sensitivity to normal endometrial epithelial cells. In the presence of Scriptaid, endometrial cancer cells and ovarian cancer cells were cultured for 2 days, and the cells were cultured in G0/G1 phase (5 μm Scriptaid treatment) and G2/M phase (10 μm Scriptaid treatment). Accumulation, while the S-phase proportion decreases accordingly. 10 μm Scriptaid induced apoptosis and mitochondrial membrane potential loss in 56.1% of Ishikawa cells, and decreased cyclin A and bcl-2 levels by 50% and 20%, respectively. |